Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VHX-896 and iloperidone · 1 trial · 2 indications
As measured by plasma concentrations
| Arm | Type | Description |
|---|---|---|
| Sequence A: VHX-896 then iloperidone | EXPERIMENTAL | - |
| Sequence B: Iloperidone then VHX-896 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VHX-896 and iloperidone | DRUG | oral tablet |
| Iloperidone and VHX-896 | DRUG | oral tablet |
Inclusion Criteria: * Male or female patients 18 to 65 years of age (inclusive) * Diagnosed with either schizophrenia or bipolar I disorder, manic or mixed type, according to the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition, Text Revision (DSM-5-TR) * Patients must be symptom...
VHX-896 is an investigational small molecule being developed by Vanda Pharmaceuticals for use in schizophrenia and bipolar I disorder. It is currently in Phase 1 clinical development and has been studied in healthy volunteers as well as in patients with these conditions.
VHX-896 is a small molecule being studied as a potential treatment for schizophrenia and bipolar I disorder. The specific molecular target has not been disclosed in available clinical trial information.
VHX-896 is being developed by Vanda Pharmaceuticals Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol VNDA. The company is conducting Phase 1 clinical trials to evaluate the drug.
VHX-896 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Three Phase 1 trials have been completed, with a total enrollment of 49 participants.
VHX-896 has completed three Phase 1 trials: NCT04969211, a bioequivalence study in healthy volunteers; NCT06494397, a pharmacokinetic study in schizophrenia and bipolar I disorder; and NCT06803290, a food effect study in healthy volunteers. All trials were conducted in the United States.
VHX-896 is being studied in comparison to iloperidone tablets in bioequivalence and pharmacokinetic trials. The studies evaluate how VHX-896 compares to iloperidone, but VHX-896 is a distinct investigational drug being developed by Vanda Pharmaceuticals.